

Pan-cancer analysis reveals unique molecular patterns associated with age

1 **Pan-cancer analysis reveals unique molecular patterns associated with age**

2

3 Yajas Shah^{1,2,3,#}, Akanksha Verma^{1,2,4,#}, Andrew Marderstein^{1,2,4}, Bhavneet Bhinder^{1,2}, Olivier

4 Elemento^{1,2,3,4,*}

5

6 ¹ Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New

7 York, NY 10021, USA

8 ² Institute of Computational Biomedicine, Weill Cornell Medicine, New York, NY 10021, USA

9 ³ Physiology, Biophysics and Systems Biology Graduate Program, Weill Cornell Medicine, New

10 York, NY 10065, USA

11 ⁴ Tri-Institutional Program in Computational Biology and Medicine, Weill Cornell Medicine,

12 New York, NY 10065, USA

13

14 # These authors contributed equally

15 * Correspondence: ole2001@med.cornell.edu

Pan-cancer analysis reveals unique molecular patterns associated with age

16 **Abstract**

17 Older age is a strong risk factor for several diseases, including cancer. In cancer, older
18 age is also frequently associated with a more aggressive, treatment-refractory tumor phenotype.
19 The etiology and biology of age-associated differences among cancers are poorly understood.
20 To address this knowledge gap, we sought to delineate the differences in tumor molecular
21 characteristics between younger and older patients across a variety of tumor types. We found that
22 tumors in younger and older patients exhibit widespread molecular differences. First, we
23 observed that tumors in younger individuals, unlike those in older ones, exhibit an accelerated
24 molecular aging phenotype associated with some hallmarks of premature senescence. Second,
25 we found that tumors from younger individuals are enriched for driver gene mutations resulting
26 in homologous recombination defects. Third, we observed a trend towards a decrease in immune
27 infiltration and function in older patients and found that, immunologically, young tumor tissue
28 resembles aged healthy tissue. Taken together, we find that tumors from young individuals
29 possess unique characteristics compared to tumors in older individuals, which can potentially be
30 leveraged for differential therapeutic strategies.

Pan-cancer analysis reveals unique molecular patterns associated with age

31 **Introduction**

32 Aging refers to the decline in physiological functions with time, resulting in an increased
33 risk of disease. Although advances in healthcare have extended lifespan substantially, cancer
34 continues to be a significant contributor to global mortality. The United States projects 1.8
35 million new cancer cases and 600,000 cancer-related deaths in 2020(Siegel et al., 2020). Several
36 diseases, including cancer, are typically diagnosed in older populations. Older patients frequently
37 have worse outcomes. The molecular correlates of such age-associated differences are not
38 known.

39 Moreover, the incidence of cancer in young adults is increasing at an alarming rate
40 (Ahnen et al., 2014; Anders et al., 2009; Ben-Aharon et al., 2019). In the United States, one in
41 twenty-nine males and one in seventeen females under the age of 49 are likely to develop cancer
42 as per a recent report(Siegel et al., 2020). Tumors in the breast, colon, rectum, genital tract, skin,
43 connective tissue, and thyroid gland are the most common in this age group (Bleyer et al., 2008;
44 Jemal et al., 2010; Siegel et al., 2020).

45 It is unclear whether tumors in younger and older adults have distinct biology. Breast
46 cancers in young adults are typically larger, often harbor the triple-negative phenotype, and are
47 associated with mutations in *BRCA1*, *BRCA2*, and *TP53* (Anders et al., 2009; Lalloo et al.,
48 2006). Colorectal cancers in young adults may have a high degree of microsatellite instability
49 (MSI) and are enriched for mutations in *MYCBP2*, *BRCA2*, *PHLPP1*, *TOPORS*, and *ATR*
50 compared to older patients(Tricoli et al., 2018). While several lines of evidence suggest that
51 cancers in young adults show unique histology and survival heterogeneity, their biology has not
52 been well characterized (Bleyer et al., 2008; Keegan et al., 2016).

Pan-cancer analysis reveals unique molecular patterns associated with age

53 In this study, we conduct an unbiased analysis of primary tumors in The Cancer Genome
54 Atlas (TCGA) to understand the biology of cancers in younger vs. older individuals.
55 Furthermore, we sought to elucidate genomic, epigenomic, and transcriptomic aberrations in
56 younger and older patients and contrast them with healthy tissue. Understanding the unique
57 biology of tumors in younger and older patients may lead to personalized therapeutic strategies
58 and the development of additional biomarkers.

Pan-cancer analysis reveals unique molecular patterns associated with age

59 **Results**

60 **Identification of age-associated cancers**

61 We first sought to identify cancers with significant age-dependent outcomes in TCGA,
62 reasoning that the biology underlying the difference in outcomes may be more acute and
63 interpretable in such cancers compared to cancers with no age-associated outcome differences.
64 These cancer types were identified by a two-step filtration process involving a Cox-proportional
65 hazards model as well as differential gene expression of primary tumors. First, tumor types in
66 which the overall survival (OS) of a patient stratified by age at diagnosis were selected by Cox
67 regression using age at diagnosis as a covariate. This identified thyroid carcinoma (THCA), low-
68 grade gliomas (LGG), acute myeloid leukemia (LAML), uterine corpus endometrial carcinoma
69 (UCEC), glioblastoma multiforme (GBM), breast invasive carcinoma (BRCA), bladder
70 urothelial carcinoma (BLCA), colon adenocarcinoma (COAD), kidney renal cell carcinoma
71 (KIRC), skin cutaneous melanoma (SKCM), ovarian carcinoma (OV) and head and neck
72 squamous cell carcinoma (HNSC) as tumor types in which overall survival was inversely related
73 to age (FDR < 0.01, **Fig. 1A**, Supplementary Table 1). We divided samples from each of these
74 tumor types into quartiles based on their age of diagnosis. The first and fourth quartile served as
75 younger and older age groups, respectively (**Supplementary Fig. 1A**, Supplementary Table 2).
76 Next, we identified tumors with an age-dependent molecular phenotype by differential gene
77 expression (DGE) of younger and older groups. Tumor types that had greater than 1% of genes
78 differentially expressed between the age groups were deemed to show an age-associated
79 molecular phenotype (FDR < 0.05, **Fig. 1B**) and were selected for all further analyses. Tumor
80 types in this group included BRCA, LGG, UCEC, OV, THCA, and COAD.

Pan-cancer analysis reveals unique molecular patterns associated with age

81 We wondered whether younger age groups would be associated with early-stage tumors.
82 To our surprise, we did not find any association between age groups and tumor stage in most
83 tumor types of interest; THCA was the only tumor type that displayed this trend. In THCA,
84 Stage I tumors were associated with younger patients, while higher stages were associated with
85 older patients (FDR < 0.05, **Supplementary Fig. 1B**).

86

87 **Aging drives proliferation and immune dysfunction in cancer**

88 We sought to explore the association between age and functional aspects of tumor
89 progression. To do this, we correlated gene expression levels of commonly used tumor
90 progression markers (*MYBL2*, *TOP2A*, *PLK1*, *CCND1*, *PCNA*, and *MKI67*) with patient age. We
91 found that in most tumor types, higher gene expression levels of these markers were inversely
92 correlated with age, that is, more highly expressed in younger patients, indicating that tumors
93 from younger patients may be more aggressive than those in older ones (FDR < 0.05,
94 **Supplementary Fig. 1C**). To further explore this, we sought out to obtain a more detailed
95 understanding of transcriptional changes associated with aging in cancer using differential gene
96 expression. Of the tumor types we analyzed, we found that the BRCA, LGG, and UCEC had the
97 most differentially expressed genes between younger and older patients (**Fig. 1B**). In line with
98 the greater expression of proliferation markers in young patients, we found that gene set
99 enrichment analysis of young vs. old DGE results for KEGG pathways associated with tumor
100 growth linked younger patients to a proliferative phenotype (FDR < 0.05, **Supplementary Fig.**
101 **1D**).

102 Overall, we found that genes differentially expressed with aging show a high degree of
103 overlap across tumor types, suggesting that at least some of the biology underlying aging

Pan-cancer analysis reveals unique molecular patterns associated with age

104 processes in cancer is consistent across tissue types. Using pairwise Fisher's exact tests, we
105 found that there is a greater overlap between overexpressed genes in younger patients across
106 tumor types as compared to older ones (FDR < 0.05, **Supplemental Fig. 1E**). Seventeen genes
107 were over-expressed in younger cohorts across more than three tumor types. These genes
108 included *ZNF518B*, *EDNRA*, *GMEB1*, *PPP1R10*, and *FERMT1* and have been linked to tumor
109 growth, metastasis and poor survival in a variety of cancers (An et al., 2019; Gimeno-Valiente et
110 al., 2019; Kavela et al., 2013; Laurberg et al., 2014; Liu et al., 2017). In contrast, we found ten
111 genes to be over-expressed in old patients across at least three out of six tumor types. These
112 include *COQ3*, *EYA4*, *FERIL5*, *HOXB5*, *SYS1* and *TSNAX* and have been associated with a
113 variety of cellular functions including mitochondrial function, tumorigenesis, memory formation
114 and protein trafficking (Behnia et al., 2004; Cannon et al., 2005; Jonassen and Clarke, 2000; Lee
115 et al., 2018). Altogether these findings indicate that primary tumors in younger patients have
116 increased expression of tumor proliferation, progression, and metastasis genes. We hypothesized
117 that such tumors while having better outcomes than in older patients, are, in fact, more
118 aggressive but perhaps restrained by a more functional immune system.

119 To explore this hypothesis, we conducted gene set enrichment analyses of differential
120 expression results. This analysis showed that younger patients were enriched for pathways
121 associated with immune response in BRCA, THCA, OV, and UCEC cohorts (FDR < 0.05, **Fig.**
122 **2A**). Interestingly, we found that older patients in the LGG and COAD cohorts displayed the
123 opposite pattern and were enriched for immune-associated pathways compared to younger
124 patients, suggesting that aging-associated effects were tumor type specific. It is possible that this
125 enrichment was associated with inflammaging rather than anti-tumor immunity. Inflammaging
126 refers to inflammation commonly associated with aging and is considered to be one of the

Pan-cancer analysis reveals unique molecular patterns associated with age

127 several evolutionarily conserved pillars of senescence (Franceschi et al., 2018; Montecino-
128 Rodriguez et al., 2013; Nikolic-Žugich, 2018).

129 Next, we aimed to understand whether the previously mentioned transcriptional changes
130 reflected aging specific to cancer or were simply a consequence of healthy aging. To address this
131 question, we compared young vs. old differential gene expression results from TCGA with the
132 results from an identical analysis performed on healthy tissue (sourced from the Genotype-Tissue
133 Expression project (GTEx) project). This analysis allowed us to identify tissue-type specific
134 genes associated with aging (**Supplementary Fig. 1F**). *EYA4*, a gene associated with hearing
135 loss and cardiomyopathy(Abe et al., 2018), was over-expressed in older individuals regardless of
136 cancer status in four out of six tissue types. Similarly, *HENMT1*, *NOA1*, and *ZNF518B* were
137 over-expressed in younger individuals in three out of six tissue types. These genes have been
138 linked to piRNA methylation(Begik et al., 2020), mitochondrial function(Kolanczyk et al.,
139 2011), and tumorigenesis(Gimeno-Valiente et al., 2019).

140 We included the METABRIC dataset (breast cancer) and further investigated these
141 results at the level of activated pathways using GSEA. This analysis showed that the relationship
142 between aging in cancer and healthy aging was tumor type-dependent (**Fig. 2B**). We found that
143 in breast cancer, immune pathways (allograft rejection, IL-2 signaling, inflammatory response,
144 interferon α/γ response, complement, IL-6 signaling, apoptosis, and TNF α signaling) were
145 overall upregulated in older healthy donors and, as shown above, in young cancer patients (FDR
146 < 0.05 , **Fig. 2B**). While thyroid cancer showed a similar phenotype of pathway activation, other
147 tumor types did not display this pattern. Thus, patterns of pathway activation suggest that
148 younger breast and thyroid cancer patients resemble immunological phenotypes of aged
149 corresponding healthy tissue, indicating dysregulation of the aging process in cancer (**Fig. 2B**).

Pan-cancer analysis reveals unique molecular patterns associated with age

150 To obtain a more granular understanding of immune function, we correlated immune cell
151 infiltration (estimated using CIBERSORT(Newman et al., 2015)) with age tumor diagnosis. We
152 found that the correlation between age and specific cell types varied between tumor types (**Fig.**
153 **2C**). While we did not observe any strong correlations involving specific cell populations, we
154 found that immune cells with anti-tumor potential were predominantly associated with younger
155 populations. Indeed we found that CD8⁺ T cells were associated with younger THCA and UCEC
156 patients. Similarly, CD4⁺ resting memory T cells were associated with younger BRCA and OV
157 patients. M1 macrophages and antibody-secreting plasma cells were linked to younger BRCA
158 patients (FDR < 0.05). Interestingly, older BRCA patients showed an increase in M2
159 macrophages, and LGG patients were associated with CD8⁺ T cells (FDR < 0.05). Memory B
160 cells were associated with older patients in BRCA and UCEC (FDR < 0.05). While the role of B
161 cells in cancer is tumor-type dependent and remains controversial(Garaud et al., 2019; Zhang et
162 al., 2016), M2 macrophages are one of the major immunosuppressive species in the tumor
163 microenvironment(Pyonteck et al., 2013). However, increased T cell infiltration has been
164 unequivocally shown to result in a more robust anti-tumor response and better prognosis in
165 multiple tumor types(Hodi et al., 2010; Le et al., 2015; Topalian et al., 2012). These data are
166 concordant with increased enrichment of immune infiltrating cells in young patients.

167 Taken together, we observed that several genes associated with progression, metastasis,
168 and poor survival outcomes are associated with primary tumors from younger patients.
169 Furthermore, we show that while immune pathway enrichment with aging occurs in a tumor-type
170 specific manner, younger patients typically may harbor a more robust immune response in the
171 tumor microenvironment. This appears to balance the effect of aggressive gene expression
172 profiles (**Supplementary Fig. 1D**) found in these patients.

Pan-cancer analysis reveals unique molecular patterns associated with age

173

174 **Functional analysis of age-associated DNA methylation marks**

175 Most mammalian cells undergo global loss of DNA methylation marks and other
176 epigenetic modifications with aging, which consequently result in transcriptional imbalances (Sen
177 et al., 2016). We hypothesized that a methylation signature of aging would exist in tumors as
178 well. To test this, we identified tumor type-specific differentially methylated genes for the age
179 groups of interest (see Methods). We found that LGG and BRCA had the highest number of
180 differentially methylated genes (**Supplemental Fig. 1G**). Interestingly, a high percentage of
181 genes were hypermethylated in older patients from the COAD, THCA, and BRCA cohorts
182 (**Supplemental Fig. 1G**).

183 As expected, we found a robust association between hypomethylated and over-expressed
184 genes (**Fig. 2D**). This association was strongest in genes over-expressed in younger patients,
185 where all tumor types showed significant overlaps with hypomethylated genes (FDR < 0.05, **Fig.**
186 **2D**). In contrast, there were fewer overlaps between DNA hypomethylation and gene expression
187 of genes that were over-expressed in older populations, where only OV showed this trend.
188 We created gene lists representing the age-stratified (young or old) tumor-type specific
189 intersection of hypomethylated and over-expressed genes. Next, we conducted Reactome
190 pathway enrichment analysis (Yu and He, 2016) of these gene sets to understand epigenetically
191 driven alterations. We found that gene lists from old LGG, THCA, and UCEC patients were
192 enriched for few pathways (phases in mitosis, mTORC signaling, glycosylation), while the gene
193 list from younger BRCA patients, but not older BRCA patients, was enriched for multiple
194 pathways (Supplementary Table 3). Several pathways associated with the gene list obtained from
195 young breast cancer patients were linked to senescence (senescence associated secretory

Pan-cancer analysis reveals unique molecular patterns associated with age

196 phenotype, cellular senescence, oxidative-stress induced senescence), epigenomic
197 reprogramming (HDACs deacetylate histones, HDMs demethylate histones, DNA methylation),
198 oncogenic signaling (Wnt signaling), and DNA damage response (DNA double-strand break
199 response) (**Fig. 2E**). These features describe aging imbalance and oncogenic processes, which
200 may, in part, explain the aggressiveness of tumors from younger breast cancer patients.

201 Taken together, we show that genes that are over-expressed in younger cancer patients
202 may be epigenetically controlled. Furthermore, epigenetically controlled pathways associated
203 with young breast cancer patients, but not other cancers, are enriched for senescence, suggesting
204 dysregulated aging in the tumor.

205

206 **Tumors from young patients exhibit accelerated molecular aging and are senescent**

207 To understand the extent of aging-imbalance, we characterized the molecular age of a
208 tumor in terms of the gene expression and DNA methylation (DNAm) profiles. We estimated the
209 DNAm age from BRCA, LGG, UCEC, THCA, and COAD TCGA cohorts (Supplementary
210 Table 4) and found a weak correlation with chronological age ($R = 0.12$, $p = 6.6 \times 10^{-8}$) in primary
211 tumor samples (**Fig. 3A**). We did not estimate the DNAm age of the OV cohort since there were
212 not enough samples for statistical analysis. Interestingly, the DNAm age of healthy normal
213 adjacent tissue from TCGA (NAT) showed a high correlation with actual patient age ($R = 0.79$, p
214 $< 2.2 \times 10^{-16}$), suggesting that aberrant epigenetic landscape of the tumor alters its epigenetic age.
215 By comparing the donor age with DNAm age, we found that tumors from young and middle-
216 aged patients displayed an accelerated epigenetic age phenotype when compared to NAT (**Fig.**
217 **3B**). However, tumors from older patients did not display this phenotype as prominently, where
218 epigenetic age and actual age were much closer, suggesting that epigenetic age acceleration is

Pan-cancer analysis reveals unique molecular patterns associated with age

219 observed in younger populations. These results are in line with previous work, which showed
220 that very young breast cancer patients had accelerated epigenetic ages (Oltra et al., 2019). Indeed,
221 consistent with the findings of Horvath, 2013, apart from LGG, most tumor types tested
222 exhibited the trend of reduced age acceleration upon aging (**Fig. 3C**).

223 After observing this phenotype in DNA methylation, we aimed to recapitulate these
224 findings in gene expression data. In order to do so, we used the framework set up by Ren and
225 Kuan, 2020. Similar to the DNAm age calculator, Ren & Kuan have trained tissue-type specific
226 age predictors for RNA-Seq data. We imputed RNA age using these tissue-specific models for
227 BRCA, COAD, THCA, and UCEC (Supplementary Table 5). The analysis was limited to these
228 tumor types because Ren & Kuan do not provide regression coefficients for other tissue types, or
229 because there were no healthy samples in our dataset. Similar to the DNAm age calculator, the
230 RNA age for healthy tissue correlated with chronological age much better than tumor tissue
231 (**Supplementary Fig. 2**). Interestingly, we observed a similar trend of reduced age acceleration
232 upon aging ($p < 0.05$, **Fig. 3D**). While we did not observe accelerated aging in tumors from
233 young patients (potentially due to sample size), tumors from old patients had reduced age
234 acceleration when compared with matched healthy tissue ($p < 0.05$, **Fig. 3E**).

235 Next, we sought to further examine accelerated aging at the transcriptional level in breast
236 cancer using gene signatures of aging. We focused this analysis on breast cancer since four
237 unique datasets (TCGA-BRCA tumor, TCGA-BRCA normal tissue, METABRIC, and GTEx
238 breast tissue) were available to us. We calculated the transcriptional age of all samples using
239 single sample gene set enrichment analysis (ssGSEA) enrichment of genes upregulated with
240 aging in primary human fibroblasts (mSigDB M8910). We found that younger breast cancer
241 patients have an older tumor phenotype compared to chronologically older patients in the

Pan-cancer analysis reveals unique molecular patterns associated with age

242 TCGA-BRCA and METABRIC datasets ($p < 0.05$, **Fig. 3F**). In contrast, healthy breast tissue
243 samples obtained from GTEx and TCGA do not display a transcriptional age acceleration
244 phenotype.

245 In order to assess these changes in other tumor types, we used differential pathway
246 enrichment signals from an ssGSEA-based analysis. To do so, we estimated ssGSEA enrichment
247 scores for younger and older patients across tumor types independently and subsequently
248 calculated differential enrichment signals using a t-test. Similar to immune pathway activation
249 (**Fig. 2A**), we found that pathways associated with aging and senescence show tumor-type
250 specific patterns (**Fig. 3G**). Interestingly, younger BRCA patients were associated with almost
251 all senescence and aging pathways we could find in MSigDB. Additionally, younger THCA
252 patients were associated with cellular senescence, senescence associated secretory phenotype,
253 oncogene-induced, oxidative stress-induced, and telomere stress-induced senescence along with
254 several aging-related pathways ($FDR < 0.05$). Similarly, younger OV patients had a greater
255 enrichment score for stress induced premature senescence than old ones ($FDR < 0.05$). In
256 contrast, LGG was the only tumor type in which these pathways were differentially associated
257 with older patients.

258 Taken together, we show that molecular age acceleration and senescence are associated
259 with younger patients, rather than older. Since some senescent phenotypes have been shown to
260 promote tumor growth (Fane and Weeraratna, 2020), we show that aggressive tumor phenotypes
261 may be explained, in part, by defunct cellular pathways controlling senescence.

262

263 **Age-associated mutational profiles**

Pan-cancer analysis reveals unique molecular patterns associated with age

264 The majority of human cancers are caused by the sequential alteration of several genes
265 over the course of multiple years(Vogelstein et al., 2013). We compared somatic mutations
266 between tumors from younger and older patients in order to understand age-associated
267 mutational patterns. The most commonly mutated genes in cancers with age-dependent outcomes
268 were *TP53* (39%), *PIK3CA* (23%), *APC* (13%), and *PTEN* (13%) (**Fig. 4A**). While all variants in
269 a cancer driver genes do not have an equal impact in tumorigenesis, there is an increased
270 probability of tumor growth when driver genes carry a larger number of variants(Carter et al.,
271 2009; Torkamani and Schork, 2008). Interestingly, younger patients were enriched for mutations
272 in driver genes (*TP53*, *ATRX*, *KMT2C*, *ARID1A*) with more than one variant (FDR < 0.05,
273 Fisher's Exact Test). In line with previous research(Chalmers et al., 2017), we found that older
274 patients had a higher tumor mutation burden (TMB) in most age-associated cancers (FDR < 0.05,
275 **Fig. 4B**).

276 Since mutations in multiple driver genes are associated with aggressive clinical features,
277 we hypothesized that tumors from young patients might be enriched for driver mutations,
278 contributing to their aggressive phenotype. In order to test this hypothesis, we stratified tumor
279 type-specific driver mutations (Bailey et al., 2018) by age groups. We found that tumor-type
280 specific nonsynonymous driver gene mutations, with the exception of *EGFR* in LGG, are more
281 common in younger patients from the UCEC and LGG TCGA cohorts (FDR < 0.005, **Fig. 4C**),
282 suggesting once more that younger patients, despite their better outcome, have intrinsically more
283 aggressive tumors, at least in some tumor types. Younger LGG patients were highly enriched for
284 mutations in *TP53*, *ATRX*, and *IDH1*, and younger UCEC patients were enriched for *PTEN*,
285 *ATRX*, *CTCF*, *BRCA2*, *RPL5*, and *FAT1* in addition to other genes (Supplementary Table 6).
286 Similarly, younger breast cancer patients in the METABRIC dataset were enriched for *TP53*

Pan-cancer analysis reveals unique molecular patterns associated with age

287 mutations, while older patients were enriched for *PIK3CA* mutations (**Supplemental Fig. 3A**).
288 However, we could not detect these associations in the TCGA-BRCA dataset. Additionally,
289 younger UCEC patients were enriched for mutations in DNA damage response genes, suggesting
290 homologous recombination defects (**Supplemental Fig. 3B**). Furthermore, we report that older
291 UCEC patients are enriched for the high copy number phenotype from integrative genomic
292 clusters published by Getz et al., 2013 (FDR < 0.0001, **Fig. 4D**).

293 Next, we stratified UCEC variants by type to better understand functional alterations in
294 younger patients. We found that younger UCEC patients were enriched for frameshift insertions,
295 nonsense, nonstop, splice site, and translation start site mutations (FDR < 0.05, **Fig. 4E**).
296 Interestingly, younger patients were enriched for mutations in the PI3K-PTEN-AKT-mTOR and
297 RTK-RAS signaling pathways, while older patients had more *TP53* mutations (FDR < 0.05, **Fig.**
298 **4F**). Enrichment analysis of driver genes more frequently mutated in younger patients revealed
299 four distinct network clusters. These include *PIK3CA*/RTK-RAS signaling pathways, the beta
300 catenin pathway, DNA-damage response (DDR) pathways, and histone modulatory pathways
301 (FDR < 0.01, **Fig. 4G, Supplementary Fig. 3C-F**, Supplementary Table 7). Similar enrichment
302 analysis in old UCEC patients revealed a single cluster of *TP53* associated pathways (FDR <
303 0.05, **Supplemental Fig. 3G**, Supplementary Table 8), suggesting that tumors from young
304 UCEC patients may have a more heterogeneous mutational landscape.

305 Taken together, we show the enrichment of genomic aberrations in young patients that
306 results in more aggressive tumors. We find that younger UCEC patients are enriched for
307 mutations, while older patients exhibit a high copy number phenotype. Similarly, younger BRCA
308 patients were associated with *TP53* mutations, while older ones were associated with *PIK3CA*
309 mutations.

Pan-cancer analysis reveals unique molecular patterns associated with age

310 **Discussion**

311 Aging is a major risk factor for global morbidity and mortality, particularly for cancer
312 development. While cancers are predominantly diagnosed in older populations aged > 65 years,
313 the increasing frequency of certain tumors in young adults demands immediate attention. With
314 this focus, developing an understanding of aging-related changes in tumors may aid in refining
315 various prevention and treatment options. Recent findings have highlighted the links between
316 aging and tumor biology in specific tumor types(Kim et al., 2020; Osako et al., 2020), however,
317 none have yet performed a multi-omics comparison across tumor types. Here, we performed a
318 systematic analysis of publicly available TCGA Cohorts to elucidate the complex and unique
319 biology of tumors across younger and older age groups. We identified six TCGA tumor types
320 that exhibit an age-associated outcome and molecular phenotype. While the aging-associated
321 effects vary by tumor type, we show that these tumor types exhibit dysregulated molecular aging,
322 which drives several processes involving tumorigenesis and the anti-tumor response. We find
323 that most young patients exhibit accelerated epigenetic aging when compared to healthy
324 counterparts, potentially resulting in impaired cellular function. In addition, we find that younger
325 cancer patients often have a stronger association with aging and senescence-related pathways
326 than older ones.

327 Further, the survey of downstream biological pathways enriched in tumors as a function
328 of age enables us to uncover potential therapeutic opportunities for younger patients compared to
329 older patients, respectively. The interplay of cellular aging and tumor development in younger
330 patients has complex biology involving genomic and epigenomic defects that govern the
331 interaction of tumor cells with the stroma(Schosserer et al., 2017). Indeed, stabilizing the
332 epigenomic landscape through the use of DNA methyltransferase inhibitors (DNMTi) and

Pan-cancer analysis reveals unique molecular patterns associated with age

333 histone deacetylase inhibitors (HDACi) serve as powerful anti-tumor tools across tumor types
334 (Christmas et al., 2018; Hull et al., 2016; Rodríguez-Paredes and Esteller, 2011). DNMT and
335 HDAC1/3 inhibition have been shown to be a viable therapeutic strategy for several cancers by
336 inhibiting tumor growth as well as augmenting the anti-tumor immune response. While clinical
337 studies have not assessed differential sensitivity in young and old age groups, our analyses
338 suggest that young patients could exhibit enhanced sensitivity to such treatment regimens.
339 Recent work by Oltra et al. shows that HDAC5 inhibition differentially induces apoptosis in
340 breast cancer cell lines sourced from young patients(Oltra et al., 2020). Epigenomic
341 reprogramming of young breast cancer patients results in age-acceleration at the transcriptional
342 level as well, thereby causing gross functional alterations. We also find that young breast cancer
343 patients are enriched for senescence-associated pathways and that these changes are
344 epigenetically driven. Additionally, we report that young thyroid and endometrial cancer patients
345 are associated with senescence-related pathways at a transcriptional level.

346 We show that the senescence-associated pathways enriched in younger breast and thyroid
347 cancer patients include SASP, an IL-6 mediated secretory phenotype of persistent senescence
348 involving NF- κ B signaling, proteolytic enzymes, growth factors, cytokines, and inflammation,
349 ultimately causing tumor progression, malignant transformation, and proliferation(Di et al.,
350 2014; Gosselin et al., 2009; Krtolica et al., 2001; Malaquin et al., 2013; Mavrogonatou et al.,
351 2020). Additionally, we find that younger breast cancer patients are enriched for oxidative stress-
352 induced senescence, which promotes senescence in SASP fibroblasts, larger tumors, and
353 ultimately SASP(Hiebert et al., 2018). As co-administration of senolytic agents with traditional
354 chemotherapeutic drugs is gaining interest (Fleury et al., 2019; Gayle et al., 2019), our data

Pan-cancer analysis reveals unique molecular patterns associated with age

355 suggest that tumors from younger patients may be more susceptible to this treatment strategy
356 than older ones.

357 In addition to a senescent phenotype, we show that younger breast cancer patients are
358 enriched for immune-associated pathways. However, tumors from younger breast cancer patients
359 are often triple negative and are associated with *BRCA1* and *BRCA2* mutations, resulting in
360 aggressive tumors with poor prognosis(Anders et al., 2009; Young et al., 2009) and an increased
361 tumor mutational burden (TMB)(Lal et al., 2019). Several studies have shown a strong link
362 between TMB and the anti-tumor immune response, potentially due to an increased neoantigen
363 burden(Fernandez et al., 2019; Rizvi et al., 2015; Yarchoan et al., 2017). Given the extensive
364 epigenomic aberrations seen in young patients, it is possible that these neoantigens may be
365 epigenetically silenced. This, in turn, would lead to poor prognosis even though the patients are
366 enriched for immune pathways, potentially explaining the increased sensitivity of epigenetic
367 drugs in younger patients(Bell et al., 2018). While the datasets used for this analysis did not have
368 a substantial amount of triple negative cases, future population-based studies could test this
369 hypothesis.

370 Next, we find that younger endometrial cancer patients are particularly enriched for
371 mutations in several driver genes, including DNA damage response (DDR) genes. Although
372 pathway enrichment analysis of these genes reveals that the PI3K and RTK-RAS pathways are
373 the most mutated, clinical trials targeting these pathways have shown modest success(Dedes et
374 al., 2011; Oda et al., 2005). Mutations in DDR genes of young UCEC patients lead to
375 homologous recombination deficiencies and hypermutator phenotypes. Such populations are
376 sensitive to several therapeutic strategies, including Poly (ADP-Ribose) polymerase 1 inhibition
377 (PARPi)(McCabe et al., 2006). *PTEN* was the most differentially mutated gene in young UCEC

Pan-cancer analysis reveals unique molecular patterns associated with age

378 patients. PARPi, when coupled with *PTEN* mutations, confers synthetic lethality to such
379 tumors(Mendes-Pereira et al., 2009), suggesting an additional benefit of PARPi in young UCEC
380 patients. Additionally, we show that young LGG patients are enriched for *ATRX* and *IDHI*
381 mutations. Similar to *PTEN* in UCEC, mutations in *ATRX* confer sensitivity to combined PARPi
382 and radiotherapy(Fazal Salom et al., 2018). Furthermore, young LGG patients may be sensitive
383 to *IDHI* inhibitors such as Ivosidenib(DiNardo et al., 2018).

384 Finally, even though young patients are associated with better survival outcomes,
385 molecular data suggests they are more aggressive tumors that may be restrained by a stronger,
386 more highly activated functional immune system. We found that the gene signatures of immune
387 pathways exhibit higher expression in younger donors, with increased infiltration of B and T
388 cells (the primary cell types associated with anti-tumor immune memory). Therefore, we have
389 begun to characterize the unique biology of tumors in young adults, demonstrate that aging-
390 associated dysfunction is tumor-type specific, and explore the biological systems underlying
391 aggressive tumors. These dysregulated aging and oncogenic processes associated with the
392 aggressive tumors from young patients may be leveraged for differential therapeutic strategies
393 and biomarker discovery.

Pan-cancer analysis reveals unique molecular patterns associated with age

394 **Methods**

395 **Age Groups**

396 Previously identified quartiles served as age group limits for individual age-associated tumor
397 types from the TCGA cohort. Additionally, the quartile limits for the TCGA breast cancer cohort
398 was employed to stratify the METABRIC cohort into age groups. The GTEx cohort was,
399 however, classified as young and old using an alternate methodology. Young samples are from
400 individuals younger than 50 years, and old samples are from individuals older than 59 years.
401 This was necessary since age was a discrete variable in the GTEx dataset.

402 **Differential Gene Expression Analysis**

403 Differentially expressed genes (FDR < 0.05) between young and old age groups were identified
404 across all datasets. In the case of the microarray dataset, *limma* was run with default parameters.
405 For RNA-Seq based data, lowly expressed genes that had less than two counts per million reads
406 in more than two samples were removed from the analysis. The data was voom transformed prior
407 to fitting a linear model using *limma*(Ritchie et al., 2015). Empirical Bayes shrinkage was
408 applied to the model in both cases.

409 **Pathway Enrichment Analysis**

410 We computed pathway enrichment analysis using GSEA and Reactome pathway analysis.
411 Briefly, GSEA was computed for differential gene expression results using 1000 permutations of
412 hallmark and KEGG pathways using the *fgsea* R package(Sergushichev, 2016). We carried out
413 Reactome pathway enrichment analysis using *clusterProfiler*(Yu et al., 2012). Pathways with an
414 adjusted p-value (Benjamini-Hochberg) less than 0.05 were considered significantly enriched.

415 **Differential Methylation Analysis**

Pan-cancer analysis reveals unique molecular patterns associated with age

416 We transformed gene level beta values to m-values using the *wateRmelon* R package(Pidsley et
417 al., 2013) and subsequently identified differentially methylated genes using *limma*.

418 **ssGSEA Analysis**

419 ssGSEA was estimated using publicly available signatures on MSigDB and the *GSVA* R
420 package(Hänzelmann et al., 2013). The Poisson kernel was employed for microarray and raw
421 count data, while the Gaussian kernel was employed with TPM data. Differential analyses were
422 conducted using the Wilcoxon test and t test.

423 **DNAm Age Calculation**

424 The epigenetic age for age-dependent cancers, along with normal adjacent tissue (NAT), was
425 imputed using the online DNAm age calculator (<https://dnamage.genetics.ucla.edu/home>)
426 (Horvath, 2013). This tool predicts age from the DNAm coefficients of 353 CpG sites.
427 Imputations that correlated with the internal gold standard less than 0.8 were discarded, as
428 recommended by the tool, from downstream analyses. Groups were compared using Wilcoxon
429 tests.

430 **RNA Age Calculation**

431 We used batch corrected FPKM data (TCGA tumor, TCGA NAT and GTEx) obtained from
432 Wang et al. (Wang et al., 2018) to determine transcriptional age using the *RNAAgeCalc* R
433 package(Ren and Kuan, 2020). The regression model for imputing age was the *Dev* signature,
434 which encompassed coefficients for genes that had the largest variation across samples. Groups
435 were compared using Wilcoxon tests.

436 **Gene Overlap**

437 Pairwise comparison of differentially expressed genes ($FDR < 0.05$) between young and old
438 samples from each tumor type was performed using Fisher's exact tests from the *GeneOverlap* R

Pan-cancer analysis reveals unique molecular patterns associated with age

439 package. P-values were corrected by the Benjamini-Hochberg method. The overlap between
440 hypermethylated (FDR < 0.05) and downregulated genes (FDR < 0.05), and vice versa, was
441 similarly computed.

442 **Differential mutation analysis**

443 MAF files were obtained from GDC and METABRIC, respectively. We discarded the top 20
444 frequently mutated genes (FLAGS) in public exomes before proceeding with analyses (Shyr et
445 al., 2014). The enrichment of Single Nucleotide Variants (SNVs) in age groups per tumor type
446 was calculated using Fisher's exact test from the *maftools* R package(Mayakonda et al., 2018).
447 Tumor mutation burden (TMB) was calculated by dividing the total number of nonsynonymous
448 variants in a sample by genome size (50 MB). SNV classes and TMB were compared across age
449 groups using the Wilcoxon test.

450 **Data Availability**

451 TCGA clinical data were obtained from Liu et al.(Liu et al., 2018), CIBERSORT data from
452 Vesteinn et al. (Thorsson et al., 2018), driver gene calls from Bailey et al. (Bailey et al., 2018)
453 and TCGA-UCEC integrative genomic clusters from Getz et al. (Getz et al., 2013). Gene
454 expression data for TCGA samples using RNASeq, methylation profiling data using Illumina
455 450K, and mutect2 MAF files were downloaded from the Genomic Data Commons.
456 Preprocessed gene-level methylation data were obtained from GDAC. Batch corrected gene
457 expression data were obtained from Wang et al. (Wan g et al., 2018). Clinical data, gene
458 expression by microarray, and MAF files for the Metabric dataset(Curtis et al., 2012; Pereira et
459 al., 2016) were obtained from cbiportal(Gao et al., 2013). Gene expression using RNASeq was
460 obtained from the GTEx consortium v8 release.

461 **Code Availability**

Pan-cancer analysis reveals unique molecular patterns associated with age

462 All analyses were performed on R (www.r-project.org) version 3.5.1. Code for all analyses is
463 available on https://github.com/yajass/tcga_aging_final.

Pan-cancer analysis reveals unique molecular patterns associated with age

464 **Figure Legends**

465 **Figure 1: Tumor type selection**

466 (A) Hazard ratios (HRs) for overall survival as a function of tumor diagnosis age. HRs greater
467 than 1 are associated with decreased survival probability in older patients. Tumor types in dark
468 blue have significantly different outcomes based on age (FDR < 0.01) (B) Differentially
469 expressed genes (DEG) between younger and older patients (FDR < 0.05) from tumor types with
470 HR > 1. The bar plot indicates the fraction of DEG. Tumor types with HR > 1 and DEG > 1%
471 were termed age-associated cancers (light blue).

472 **Figure 2: Differential gene expression and methylation links immune function and** 473 **senescence to young patients**

474 (A) Gene set enrichment analysis of DEG between younger and older patients across tumor
475 types. Pathways in red are associated with older patients, and those in blue are associated with
476 younger patients (FDR < 0.05). (B) Gene set enrichment analysis of DEG between tissue sourced
477 from younger and older cancer patients (black) as well as corresponding healthy individuals
478 (grey). (C) Pearson correlation coefficients of CIBERSORT (relative) scores with age across
479 tumor types (FDR < 0.05). (D) The bar plots show the overlap between hypomethylated and
480 over-expressed genes in young (top) and old patients (bottom). (E) Reactome pathway
481 enrichment analysis of hypomethylated and over-expressed genes. Point size reflects the ratio of
482 the number of genes present in the differential gene list and the number of genes present in the
483 pathway.

484 **Figure 3: Young patients are associated with senescence and accelerated aging**

485 (A) Scatterplot of DNA methylation age and chronological age in tumor (dark blue) and healthy
486 (red) tissue. (B) The difference between DNA methylation age and chronological age (DNAm

Pan-cancer analysis reveals unique molecular patterns associated with age

487 age acceleration difference) is plotted against chronological age bins. (C) DNAm age
488 acceleration difference is plotted against age bins for breast cancer (dark green), colon cancer
489 (light brown), low grade glioma (blue), thyroid cancer (dark brown), and uterine endometrial
490 carcinoma (green). (D) The difference between RNA age and chronological age (RNA age
491 acceleration difference) is plotted against age bins for tumor (dark blue) and normal (red)
492 samples. (E) Paired analysis of RNA age acceleration difference in younger and older patients.
493 (F) Single sample gene set enrichment analysis of genes associated with aging in healthy (top)
494 and tumor (bottom) breast samples. (G) The scatter plot shows BH-adjusted p values for
495 differential pathway enrichment analysis between young (filled circles) and old (hollow circles)
496 patients from the BRCA (dark green), COAD (light brown), LGG (blue), OV (dark brown),
497 THCA (green) and UCEC (purple) TCGA cohorts.

498 **Figure 4: Mutation Analysis**

499 (A) Oncoplot of the top 10 most frequently mutated genes in BRCA, COAD, LGG, OV, THCA,
500 and UCEC. (B) Comparison of tumor mutation burden in younger (blue) and older (yellow)
501 patients. Stars indicate BH-adjusted p values. (C) The forest plot shows tumor-type specific
502 driver gene mutations more commonly found in younger (blue) and older patients ($FDR <$
503 0.005). (D) Stacked bar plots show the relative proportion of integrative genomic clusters in
504 younger and older UCEC patients. (E) Boxplots show the frequency of variants in younger (blue)
505 and older (yellow) UCEC patients. Stars indicate BH-adjusted p values. (F) Oncoplot shows
506 mutations that are differentially enriched in younger and older UCEC patients ($FDR < 0.05$) and
507 is accompanied by a lollipop plot of PTEN. (G) Reactome pathway analysis of driver genes
508 mutated in young UCEC patients. Nodes represent the fraction of the number of mutated genes
509 associated with young UCEC patients ($FDR < 0.05$) and pathway size. Edges represent the

Pan-cancer analysis reveals unique molecular patterns associated with age

510 number of shared genes across pathways.

511

512 **Figure S1:**

513 (A) Age distribution that classifies patients as younger and older. (B) The forest plot shows the
514 association between tumor stage and age. Tumor stages with a log odds ratio greater than 0 are
515 associated with older patients. (C) Gene expression correlation coefficients (Spearman) with age
516 for genes associated with tumor progression markers are visualized as a heatmap. Stars indicate
517 BH-adjusted p values. (D) Gene set enrichment analysis of DEG for KEGG pathways associated
518 with tumor proliferation. Pathways in red are associated with older patients, and those in blue are
519 associated with younger patients (FDR < 0.05). (E) The overlap between DEGs associated with
520 young (blue) and old (red) patients visualized as a heatmap. The color gradient reflects log odds
521 ratios, and stars indicate BH-adjusted p values. (F) The Venn diagrams show the overlap
522 between DEGs (FDR < 0.05) associated with young and old individuals across tumor (TCGA)
523 and healthy (GTEx) datasets. (G) The total number of differentially methylated genes (DMG) in
524 younger and older patients are visualized (top). Stacked bar plots represent relative amounts of
525 hypermethylation status in younger (blue) and older (yellow) patients.

526 **Figure S2: Scatter plots of imputed RNA age and chronological age for TCGA and GTEx**

527 **datasets**

528 **Figure S3:**

529 (A) Oncoplot of differential mutations in younger and older patients from the METABRIC
530 dataset (FDR < 0.05) along with a lollipop plot showing the type of P53 variants. (B) The
531 heatmap displays mutation status in DNA damage response genes. Black areas represent mutated
532 genes. (C-F) Oncoplots of the RTK-RAS and PI3K pathways for younger and older patients.

Pan-cancer analysis reveals unique molecular patterns associated with age

533 Genes in blue are oncogenes, while genes in red are tumor suppressor genes. (G) The network
534 diagram represents reactome pathway enrichment analysis of driver genes in older UCEC
535 patients. Nodes represent the fraction of the number of mutated genes associated with old UCEC
536 patients ($FDR < 0.05$) and pathway size. Edges represent the number of shared genes across
537 pathways.

Pan-cancer analysis reveals unique molecular patterns associated with age

538 **References**

- 539 Abe, S., Takeda, H., Nishio, S. ya, and Usami, S. ichi (2018). Sensorineural hearing loss and
540 mild cardiac phenotype caused by an EYA4 mutation. *Hum. Genome Var.* 5, 1–4.
- 541 Ahnen, D.J., Wade, S.W., Jones, W.F., Sifri, R., Silveiras, J.M., Greenamyre, J., Guiffre, S.,
542 Axilbund, J., Spiegel, A., and You, Y.N. (2014). The increasing incidence of young-onset
543 colorectal cancer: A call to action. *Mayo Clin. Proc.* 89, 216–224.
- 544 An, W., Yao, S., Sun, X., Hou, Z., Lin, Y., Su, L., and Liu, X. (2019). Glucocorticoid
545 modulatory element-binding protein 1 (GMEB1) interacts with the de-ubiquitinase USP40 to
546 stabilize CFLAR L and inhibit apoptosis in human non-small cell lung cancer cells. *J. Exp. Clin.*
547 *Cancer Res.* 38, 181.
- 548 Anders, C.K., Johnson, R., Litton, J., Phillips, M., and Bleyer, A. (2009). Breast Cancer Before
549 Age 40 Years. *Semin. Oncol.* 36, 237–249.
- 550 Bailey, M.H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A.,
551 Colaprico, A., Wendl, M.C., Kim, J., Reardon, B., et al. (2018). Comprehensive Characterization
552 of Cancer Driver Genes and Mutations. *Cell* 173, 371-385.e18.
- 553 Begik, O., Lucas, M.C., Liu, H., Ramirez, J.M., Mattick, J.S., and Novoa, E.M. (2020).
554 Integrative analyses of the RNA modification machinery reveal tissue- And cancer-specific
555 signatures. *Genome Biol.* 21, 1–24.
- 556 Behnia, R., Panic, B., Whyte, J.R.C., and Munro, S. (2004). Targeting of the Arf-like GTPase
557 Arl3p to the Golgi requires N-terminal acetylation and the membrane protein Sys1p. *Nat. Cell*
558 *Biol.* 6, 405–413.
- 559 Bell, J.A., Galaznik, A., Huelin, R., Stokes, M., Guo, Y., Fram, R.J., and Faller, D. V. (2018).
560 Systematic Literature Review of Treatment Options and Clinical Outcomes for Patients With

Pan-cancer analysis reveals unique molecular patterns associated with age

- 561 Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. *Clin.*
562 *Lymphoma, Myeloma Leuk.* *18*, e157–e166.
- 563 Ben-Aharon, I., Elkabets, M., Pelossof, R., Yu, K.H., Iacubuzio-Donahue, C.A., Leach, S.D.,
564 Lowery, M.A., Goodman, K.A., and O'Reilly, E.M. (2019). Genomic landscape of pancreatic
565 adenocarcinoma in younger versus older patients: Does age matter? *Clin. Cancer Res.* *25*, 2185–
566 2193.
- 567 Bleyer, A., Barr, R., Hayes-Lattin, B., Thomas, D., Ellis, C., and Anderson, B. (2008). The
568 distinctive biology of cancer in adolescents and young adults. *Nat. Rev. Cancer* *8*, 288–298.
- 569 Cannon, T.D., Hennah, W., Van Erp, T.G.M., Thompson, P.M., Lonnqvist, J., Huttunen, M.,
570 Gasperoni, T., Tuulio-Henriksson, A., Pirkola, T., Toga, A.W., et al. (2005). Association of
571 DISC1/TRAX haplotypes with schizophrenia, reduced prefrontal gray matter, and impaired
572 short- and long-term memory. *Arch. Gen. Psychiatry* *62*, 1205–1213.
- 573 Carter, H., Chen, S., Isik, L., Tyekucheva, S., Velculescu, V.E., Kinzler, K.W., Vogelstein, B.,
574 and Karchin, R. (2009). Cancer-specific high-throughput annotation of somatic mutations:
575 Computational prediction of driver missense mutations. *Cancer Res.* *69*, 6660–6667.
- 576 Chalmers, Z.R., Connelly, C.F., Fabrizio, D., Gay, L., Ali, S.M., Ennis, R., Schrock, A.,
577 Campbell, B., Shlien, A., Chmielecki, J., et al. (2017). Analysis of 100,000 human cancer
578 genomes reveals the landscape of tumor mutational burden. *Genome Med.* *9*, 34.
- 579 Christmas, B.J., Rafie, C.I., Hopkins, A.C., Scott, B.A., Ma, H.S., Cruz, K.A., Woolman, S.,
580 Armstrong, T.D., Connolly, R.M., Azad, N.A., et al. (2018). Entinostat converts immune-
581 resistant breast and pancreatic cancers into checkpoint-responsive tumors by reprogramming
582 tumor-infiltrating MDSCs. *Cancer Immunol. Res.* *6*, 1561–1577.
- 583 Curtis, C., Shah, S.P., Chin, S.F., Turashvili, G., Rueda, O.M., Dunning, M.J., Speed, D., Lynch,

Pan-cancer analysis reveals unique molecular patterns associated with age

- 584 A.G., Samarajiwa, S., Yuan, Y., et al. (2012). The genomic and transcriptomic architecture of
585 2,000 breast tumours reveals novel subgroups. *Nature* 486, 346–352.
- 586 Dedes, K.J., Wetterskog, D., Ashworth, A., Kaye, S.B., and Reis-Filho, J.S. (2011). Emerging
587 therapeutic targets in endometrial cancer. *Nat. Rev. Clin. Oncol.* 8, 261–271.
- 588 Di, G.H., Liu, Y., Lu, Y., Liu, J., Wu, C., and Duan, H.F. (2014). IL-6 secreted from senescent
589 mesenchymal stem cells promotes proliferation and migration of breast cancer cells. *PLoS One*
590 9.
- 591 DiNardo, C.D., Stein, E.M., de Botton, S., Roboz, G.J., Altman, J.K., Mims, A.S., Swords, R.,
592 Collins, R.H., Mannis, G.N., Pollyea, D.A., et al. (2018). Durable Remissions with Ivosidenib in
593 *IDH1* -Mutated Relapsed or Refractory AML. *N. Engl. J. Med.* 378, 2386–2398.
- 594 Fane, M., and Weeraratna, A.T. (2020). How the ageing microenvironment influences tumour
595 progression. *Nat. Rev. Cancer* 20, 89–106.
- 596 Fazal Salom, J., Bjerke, L., Carvalho, D., Boulton, J., Mackay, A., Pemberton, H., Molinari, V.,
597 Clarke, M., Vinci, M., Carceller, F., et al. (2018). PDTM-33. ATRX LOSS CONFERS
598 ENHANCED SENSITIVITY TO COMBINED PARP INHIBITION AND RADIOTHERAPY
599 IN PAEDIATRIC GLIOBLASTOMA MODELS. *Neuro. Oncol.* 20, vi210–vi211.
- 600 Fernandez, E.M., Eng, K., Beg, S., Beltran, H., Faltas, B.M., Mosquera, J.M., Nanus, D.M.,
601 Pisapia, D.J., Rao, R.A., Robinson, B.D., et al. (2019). Cancer-Specific Thresholds Adjust for
602 Whole Exome Sequencing–Based Tumor Mutational Burden Distribution. *JCO Precis. Oncol.* 3,
603 1–12.
- 604 Fleury, H., Malaquin, N., Tu, V., Gilbert, S., Martinez, A., Olivier, M.A., Sauriol, A.,
605 Communal, L., Leclerc-Desaulniers, K., Carmona, E., et al. (2019). Exploiting interconnected
606 synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence. *Nat.*

Pan-cancer analysis reveals unique molecular patterns associated with age

607 Commun. *10*, 1–15.

608 Franceschi, C., Garagnani, P., Parini, P., Giuliani, C., and Santoro, A. (2018). Inflammaging: a
609 new immune–metabolic viewpoint for age-related diseases. *Nat. Rev. Endocrinol.* *14*, 576–590.

610 Gao, J., Aksoy, B.A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S.O., Sun, Y., Jacobsen, A.,
611 Sinha, R., Larsson, E., et al. (2013). Integrative analysis of complex cancer genomics and clinical
612 profiles using the cBioPortal. *Sci. Signal.* *6*, p11.

613 Garaud, S., Buisseret, L., Solinas, C., Gu-Trantien, C., De Wind, A., Van Den Eynden, G.,
614 Naveaux, C., Lodewyckx, J.N., Boisson, A., Duvillier, H., et al. (2019). Tumor-infiltrating B
615 cells signal functional humoral immune responses in breast cancer. *JCI Insight* *4*.

616 Gayle, S.S., Sahni, J.M., Webb, B.M., Weber-Bonk, K.L., Shively, M.S., Spina, R., Bar, E.E.,
617 Summers, M.K., and Keri, R.A. (2019). Targeting BCL-xL improves the efficacy of
618 bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting
619 the death of senescent cells. *J. Biol. Chem.* *294*, 875–886.

620 Getz, G., Gabriel, S.B., Cibulskis, K., Lander, E., Sivachenko, A., Sougnez, C., Lawrence, M.,
621 Kandoth, C., Dooling, D., Fulton, R., et al. (2013). Integrated genomic characterization of
622 endometrial carcinoma. *Nature* *497*, 67–73.

623 Gimeno-Valiente, F., Riffo-Campos, Á.L., Vallet-Sánchez, A., Siscar-Lewin, S., Gambardella,
624 V., Tarazona, N., Cervantes, A., Franco, L., Castillo, J., and López-Rodas, G. (2019). ZNF518B
625 gene up-regulation promotes dissemination of tumour cells and is governed by epigenetic
626 mechanisms in colorectal cancer. *Sci. Rep.* *9*, 1–12.

627 Gosselin, K., Martien, S., Pourtier, A., Vercamer, C., Ostoich, P., Morat, L., Sabatier, L.,
628 Duprez, L., De Roodenbeke, C.T.K., Gilson, E., et al. (2009). Senescence-associated oxidative
629 DNA damage promotes the generation of neoplastic cells. *Cancer Res.* *69*, 7917–7925.

Pan-cancer analysis reveals unique molecular patterns associated with age

- 630 Hänzelmann, S., Castelo, R., and Guinney, J. (2013). GSEA: Gene set variation analysis for
631 microarray and RNA-Seq data. *BMC Bioinformatics* *14*, 7.
- 632 Hiebert, P., Wietcha, M.S., Cangkrama, M., Haertel, E., Mavrogonatou, E., Stumpe, M.,
633 Steenbock, H., Grossi, S., Beer, H.D., Angel, P., et al. (2018). Nrf2-Mediated Fibroblast
634 Reprogramming Drives Cellular Senescence by Targeting the Matrisome. *Dev. Cell* *46*, 145-
635 161.e10.
- 636 Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez,
637 R., Robert, C., Schadendorf, D., Hassel, J.C., et al. (2010). Improved survival with ipilimumab in
638 patients with metastatic melanoma. *N. Engl. J. Med.* *363*, 711–723.
- 639 Horvath, S. (2013). DNA methylation age of human tissues and cell types. *Genome Biol.* *14*,
640 R115.
- 641 Hull, E.E., Montgomery, M.R., and Leyva, K.J. (2016). HDAC Inhibitors as Epigenetic
642 Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases.
643 *Biomed Res. Int.* *2016*.
- 644 Jemal, A., Siegel, R., Xu, J., and Ward, E. (2010). Cancer Statistics, 2010. *CA. Cancer J. Clin.*
645 *60*, 277–300.
- 646 Jonassen, T., and Clarke, C.F. (2000). Isolation and functional expression of human COQ3, a
647 gene encoding a methyltransferase required for ubiquinone biosynthesis. *J. Biol. Chem.* *275*,
648 12381–12387.
- 649 Kavela, S., Shinde, S.R., Ratheesh, R., Viswakalyan, K., Bashyam, M.D., Gowrishankar, S.,
650 Vamsy, M., Pattnaik, S., Rao, S., Sastry, R.A., et al. (2013). PNUTS functions as a proto-
651 oncogene by sequestering PTEN. *Cancer Res.* *73*, 205–214.
- 652 Keegan, T.H.M., Ries, L.A.G., Barr, R.D., Geiger, A.M., Dahlke, D.V., Pollock, B.H., and

Pan-cancer analysis reveals unique molecular patterns associated with age

- 653 Bleyer, W.A. (2016). Comparison of cancer survival trends in the United States of adolescents
654 and young adults with those in children and older adults. *Cancer* 122, 1009–1016.
- 655 Kim, Y.-J., Kim, K., Lee, K.H., Kim, J., and Jung, W. (2020). Immune expression signatures as
656 candidate prognostic biomarkers of age and gender survival differences in cutaneous melanoma.
657 *Sci. Rep.* 10, 12322.
- 658 Kolanczyk, M., Pech, M., Zemojtel, T., Yamamoto, H., Mikula, I., Calvaruso, M.A., Van Den
659 Brand, M., Richter, R., Fischer, B., Ritz, A., et al. (2011). NOA1 is an essential GTPase required
660 for mitochondrial protein synthesis. *Mol. Biol. Cell* 22, 1–11.
- 661 Krtolica, A., Parrinello, S., Lockett, S., Desprez, P.Y., and Campisi, J. (2001). Senescent
662 fibroblasts promote epithelial cell growth and tumorigenesis: A link between cancer and aging.
663 *Proc. Natl. Acad. Sci. U. S. A.* 98, 12072–12077.
- 664 Lal, A., Ramazzotti, D., Weng, Z., Liu, K., Ford, J.M., and Sidow, A. (2019). Comprehensive
665 genomic characterization of breast tumors with BRCA1 and BRCA2 mutations. *BMC Med.*
666 *Genomics* 12, 84.
- 667 Lalloo, F., Varley, J., Moran, A., Ellis, D., O’Dair, L., Pharoah, P., Antoniou, A., Hartley, R.,
668 Shenton, A., Seal, S., et al. (2006). BRCA1, BRCA2 and TP53 mutations in very early-onset
669 breast cancer with associated risks to relatives. *Eur. J. Cancer* 42, 1143–1150.
- 670 Laurberg, J.R., Jensen, J.B., Schepeler, T., Borre, M., Ørntoft, T.F., and Dyrskjøt, L. (2014).
671 High expression of GEM and EDNRA is associated with metastasis and poor outcome in patients
672 with advanced bladder cancer. *BMC Cancer* 14.
- 673 Le, D.T., Uram, J.N., Wang, H., Bartlett, B.R., Kemberling, H., Eyring, A.D., Skora, A.D.,
674 Luber, B.S., Azad, N.S., Laheru, D., et al. (2015). PD-1 Blockade in Tumors with Mismatch-
675 Repair Deficiency. *N. Engl. J. Med.* 372, 2509–2520.

Pan-cancer analysis reveals unique molecular patterns associated with age

- 676 Lee, J.Y., Kim, J.M., Jeong, D.S., and Kim, M.H. (2018). Transcriptional activation of EGFR by
677 HOXB5 and its role in breast cancer cell invasion. *Biochem. Biophys. Res. Commun.* *503*,
678 2924–2930.
- 679 Liu, C.C., Cai, D.L., Sun, F., Wu, Z.H., Yue, B., Zhao, S.L., Wu, X.S., Zhang, M., Zhu, X.W.,
680 Peng, Z.H., et al. (2017). FERMT1 mediates epithelial-mesenchymal transition to promote colon
681 cancer metastasis via modulation of β -catenin transcriptional activity. *Oncogene* *36*, 1779–1792.
- 682 Liu, J., Lichtenberg, T., Hoadley, K.A., Poisson, L.M., Lazar, A.J., Cherniack, A.D., Kovatich,
683 A.J., Benz, C.C., Levine, D.A., Lee, A. V., et al. (2018). An Integrated TCGA Pan-Cancer
684 Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. *Cell* *173*, 400-
685 416.e11.
- 686 Malaquin, N., Vercamer, C., Bouali, F., Martien, S., Deruy, E., Wernert, N., Chwastyniak, M.,
687 Pinet, F., Abbadie, C., and Pourtier, A. (2013). Senescent Fibroblasts Enhance Early Skin
688 Carcinogenic Events via a Paracrine MMP-PAR-1 Axis. *PLoS One* *8*, e63607.
- 689 Mavrogonatou, E., Pratsinis, H., and Kletsas, D. (2020). The role of senescence in cancer
690 development. *Semin. Cancer Biol.* *62*, 182–191.
- 691 Mayakonda, A., Lin, D.C., Assenov, Y., Plass, C., and Koeffler, H.P. (2018). Maftools: Efficient
692 and comprehensive analysis of somatic variants in cancer. *Genome Res.* *28*, 1747–1756.
- 693 McCabe, N., Turner, N.C., Lord, C.J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S.,
694 O'Connor, M.J., Tutt, A.N., Zdzienicka, M.Z., et al. (2006). Deficiency in the repair of DNA
695 damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase
696 inhibition. *Cancer Res.* *66*, 8109–8115.
- 697 Mendes-Pereira, A.M., Martin, S.A., Brough, R., McCarthy, A., Taylor, J.R., Kim, J.S.,
698 Waldman, T., Lord, C.J., and Ashworth, A. (2009). Synthetic lethal targeting of PTEN mutant

Pan-cancer analysis reveals unique molecular patterns associated with age

699 cells with PARP inhibitors. *EMBO Mol. Med.* *1*, 315–322.

700 Montecino-Rodriguez, E., Berent-Maoz, B., and Dorshkind, K. (2013). Causes, consequences,
701 and reversal of immune system aging. *J. Clin. Invest.* *123*, 958.

702 Newman, A.M., Liu, C.L., Green, M.R., Gentles, A.J., Feng, W., Xu, Y., Hoang, C.D., Diehn,
703 M., and Alizadeh, A.A. (2015). Robust enumeration of cell subsets from tissue expression
704 profiles. *Nat. Methods* *12*, 453–457.

705 Nikolich-Zugich, J. (2018). The twilight of immunity: Emerging concepts in aging of the
706 immune system review-article. *Nat. Immunol.* *19*, 10–19.

707 Oda, K., Stokoe, D., Taketani, Y., and McCormick, F. (2005). High frequency of coexistent
708 mutations of PIK3CA and PTEN genes in endometrial carcinoma. *Cancer Res.* *65*, 10669–
709 10673.

710 Oltra, S.S., Peña-Chilet, M., Flower, K., Martinez, M.T., Alonso, E., Burgues, O., Lluch, A.,
711 Flanagan, J.M., and Ribas, G. (2019). Acceleration in the DNA methylation age in breast cancer
712 tumours from very young women. *Sci. Rep.* *9*, 14991.

713 Oltra, S.S., Cejalvo, J.M., Tormo, E., Albanell, M., Ferrer, A., Nacher, M., Bermejo, B.,
714 Hernando, C., Chirivella, I., Alonso, E., et al. (2020). HDAC5 Inhibitors as a Potential Treatment
715 in Breast Cancer Affecting Very Young Women. *Cancers (Basel)*. *12*, 412.

716 Osako, T., Lee, H., Turashvili, G., Chiu, D., McKinney, S., Joosten, S.E.P., Wilkinson, D.,
717 Nielsen, T.O., Zwart, W., Emerman, J.T., et al. (2020). Age-correlated protein and transcript
718 expression in breast cancer and normal breast tissues is dominated by host endocrine effects. *Nat.*
719 *Cancer* *1*, 518–532.

720 Pereira, B., Chin, S.F., Rueda, O.M., Vollan, H.K.M., Provenzano, E., Bardwell, H.A., Pugh, M.,
721 Jones, L., Russell, R., Sammut, S.J., et al. (2016). The somatic mutation profiles of 2,433 breast

Pan-cancer analysis reveals unique molecular patterns associated with age

722 cancers refines their genomic and transcriptomic landscapes. *Nat. Commun.* 7, 1–16.

723 Pidsley, R., Y Wong, C.C., Volta, M., Lunnon, K., Mill, J., and Schalkwyk, L.C. (2013). A data-
724 driven approach to preprocessing Illumina 450K methylation array data. *BMC Genomics* 14,
725 293.

726 Pyonteck, S.M., Akkari, L., Schuhmacher, A.J., Bowman, R.L., Sevenich, L., Quail, D.F., Olson,
727 O.C., Quick, M.L., Huse, J.T., Teijeiro, V., et al. (2013). CSF-1R inhibition alters macrophage
728 polarization and blocks glioma progression. *Nat. Med.* 19, 1264–1272.

729 Ren, X., and Kuan, P.F. (2020). RNAAgeCalc: A multi-tissue transcriptional age calculator.
730 *BioRxiv* 2020.02.14.950188.

731 Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W., and Smyth, G.K. (2015). limma
732 powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic
733 Acids Res.* 43.

734 Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., Lee, W.,
735 Yuan, J., Wong, P., Ho, T.S., et al. (2015). Mutational landscape determines sensitivity to PD-1
736 blockade in non-small cell lung cancer. *Science* (80-.). 348, 124–128.

737 Rodríguez-Paredes, M., and Esteller, M. (2011). Cancer epigenetics reaches mainstream
738 oncology. *Nat. Med.* 17, 330–339.

739 Schosserer, M., Grillari, J., and Breitenbach, M. (2017). The dual role of cellular senescence in
740 developing tumors and their response to cancer therapy. *Front. Oncol.* 7, 278.

741 Sen, P., Shah, P.P., Nativio, R., and Berger, S.L. (2016). Epigenetic Mechanisms of Longevity
742 and Aging. *Cell* 166, 822–839.

743 Sergushichev, A.A. (2016). An algorithm for fast preranked gene set enrichment analysis using
744 cumulative statistic calculation. *BioRxiv* 060012.

Pan-cancer analysis reveals unique molecular patterns associated with age

- 745 Shyr, C., Tarailo-Graovac, M., Gottlieb, M., Lee, J.J.Y., Van Karnebeek, C., and Wasserman,
746 W.W. (2014). FLAGS, frequently mutated genes in public exomes. *BMC Med. Genomics* 7.
- 747 Siegel, R.L., Miller, K.D., and Jemal, A. (2020). Cancer statistics, 2020. *CA. Cancer J. Clin.* 70,
748 7–30.
- 749 Thorsson, V., Gibbs, D.L., Brown, S.D., Wolf, D., Bortone, D.S., Ou Yang, T.H., Porta-Pardo,
750 E., Gao, G.F., Plaisier, C.L., Eddy, J.A., et al. (2018). The Immune Landscape of Cancer.
751 *Immunity* 48, 812-830.e14.
- 752 Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F.,
753 Powderly, J.D., Carvajal, R.D., Sosman, J.A., Atkins, M.B., et al. (2012). Safety, Activity, and
754 Immune Correlates of Anti-PD-1 Antibody in Cancer. *N. Engl. J. Med.* 366, 2443–2454.
- 755 Torkamani, A., and Schork, N.J. (2008). Prediction of cancer driver mutations in protein kinases.
756 *Cancer Res.* 68, 1675–1682.
- 757 Tricoli, J. V., Boardman, L.A., Patidar, R., Sindiri, S., Jang, J.S., Walsh, W.D., McGregor, P.M.,
758 Camalier, C.E., Mehaffey, M.G., Furman, W.L., et al. (2018). A mutational comparison of adult
759 and adolescent and young adult (AYA) colon cancer. *Cancer* 124, 1070–1082.
- 760 Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A., and Kinzler, K.W.
761 (2013). Cancer genome landscapes. *Science* (80-.). 340, 1546–1558.
- 762 Wang, Q., Armenia, J., Zhang, C., Penson, A. V., Reznik, E., Zhang, L., Minet, T., Ochoa, A.,
763 Gross, B.E., Iacobuzio-Donahue, C.A., et al. (2018). Data Descriptor: Unifying cancer and
764 normal RNA sequencing data from different sources. *Sci. Data* 5, 1–8.
- 765 Yarchoan, M., Hopkins, A., and Jaffee, E.M. (2017). Tumor mutational burden and response rate
766 to PD-1 inhibition. *N. Engl. J. Med.* 377, 2500–2501.
- 767 Young, S.R., Pilarski, R.T., Donenberg, T., Shapiro, C., Hammond, L.S., Miller, J., Brooks,

Pan-cancer analysis reveals unique molecular patterns associated with age

- 768 K.A., Cohen, S., Tenenholz, B., DeSai, D., et al. (2009). The prevalence of BRCA1 mutations
769 among young women with triple-negative breast cancer. *BMC Cancer* *9*, 86.
- 770 Yu, G., and He, Q.Y. (2016). ReactomePA: An R/Bioconductor package for reactome pathway
771 analysis and visualization. *Mol. Biosyst.* *12*, 477–479.
- 772 Yu, G., Wang, L.G., Han, Y., and He, Q.Y. (2012). ClusterProfiler: An R package for comparing
773 biological themes among gene clusters. *Omi. A J. Integr. Biol.* *16*, 284–287.
- 774 Zhang, C., Xin, H., Zhang, W., Yazaki, P.J., Zhang, Z., Le, K., Li, W., Lee, H., Kwak, L.,
775 Forman, S., et al. (2016). CD5 Binds to Interleukin-6 and Induces a Feed-Forward Loop with the
776 Transcription Factor STAT3 in B Cells to Promote Cancer. *Immunity* *44*, 913–923.
- 777

Figure 1




Figure 2




Figure 3




Figure 4




Figure S1




Figure S2

medRxiv preprint doi: <https://doi.org/10.1101/2020.08.30.20184762>; this version posted September 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).




Figure S3

